Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair, skin, and sexual wellness, has launched a clinical trial designed to explore the effectiveness of an improved formulation of NoStingz jellyfish sting prevention sunscreen against man-o-war jellyfish. The trial, which will be led by Dr. Patric Rice and Dr. Eric Stroud, will be conducted by Angelshark Consulting; the trial will take place in the Florida Keys. The company called the launch of the trial a “milestone” and noted that the trial will be focused on evaluating the human response to stings from man-o-war jellyfish when protective sunscreen developed by Jupiter is applied.
“We are thrilled to launch this clinical trial and take a major step forward in providing our customers with a dependable sunscreen solution that can protect them from man-o-war jellyfish stings,” said Jupiter Wellness CEO Brian John in the press release. “We have already seen great results from our product, and we have the data and user testimonials to back it up. This trial is specifically targeting the man-o-war jellies, which are known to have some of the most painful stings in our waters. The data generated from this trial will be invaluable in helping us develop more effective and safer sunscreen products.”
To view the full press release, visit https://ibn.fm/r6rZh
About Jupiter Wellness Inc.
Jupiter Wellness is a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”) products and intellectual property. The company’s product pipeline addresses a range of conditions, including hair loss, eczema, burns and sexual wellness. Revenue is generated through the sales of OTC and consumer products, contract research agreements and licensing royalties. For additional information about this company, please visit www.JupiterWellnessInc.com.
NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork